Aurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned Mar 29, 2016
Aurinia Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Operational Highlights Mar 18, 2016
Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis Mar 2, 2016
Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis Feb 8, 2016
Aurinia Pharmaceuticals to Present at the Canaccord Genuity Rare Disease and Bio-Pharma One on One Day Jan 29, 2016
